

Cell Therapy Commercialization – How short term gain can lead to long term pain

David James

CEO, Scinogy

David is an internationally recognized Executive who has spent more than 30 years commercializing innovative technologies, with the past 15 years focussed on the Cell Therapy and Diagnostic markets.

David is a regular conference speaker, guest lecturer for the Department of Chemical and Biomedical Engineering (University of Melbourne) and author of several articles. His whitepaper titled “How short-term gain can lead to long-term pain” published in the BioInsights in 2017, has become a key reference document for the rapidly advancing CAR-T therapy field.

In 2016 David and his two partners formed Scinogy, a Melbourne based start-up company, with the primary purpose of addressing the development and scale-up challenges confronting the cell therapy industry. Through their global consulting work they recognized that the approach being used to develop cell therapies was not scalable, transferable or commercially viable. What was lacking were appropriate strategies and technologies. Scinogy's solutions, including the soon-to-be released ROTEA™, are specifically designed for cell therapy development and manufacture and are setting a new benchmark in performance.



DATE

**THURS 1
NOVEMBER**

TIME

12.00PM – 1.00PM

LOCATION

**TRF BUILDING
LEVEL 2, SEMINAR
ROOMS 1 + 2**